3-二甲基氨基吡咯烷e-1-硫代甲酰胺 | 473706-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 3-二甲基氨基吡咯烷e-1-硫代甲酰胺
• 英文名称: 3-dimethylamino-pyrrolidine-1-carbothioic acid amide
• 英文别名: 3-(dimethylamino)-1-pyrrolidinecarbothioamide；3-(dimethylamino)pyrrolidine-1-carbothioamide
• CAS: 473706-91-1
• 化学式: C₇H₁₅N₃S
• 分子量: 173.282
• InChiKey: RKANZVPXFYNLBS-UHFFFAOYSA-N

物化性质

• 沸点：
  268.2±50.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-二甲基氨基吡咯烷e-1-硫代甲酰胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (2R)-N-(cyanomethyl)-2-[3-[3-[2-[3-(dimethylamino)pyrrolidin-1-yl]-1,3-thiazol-4-yl]phenyl]phenyl]-4-methylpentanamide
  参考文献：
  名称：

  组织蛋白酶K的四环非肽联芳腈抑制剂的设计与合成。

  摘要：

  描述了一系列新型和有效的半胱氨酸蛋白酶组织蛋白酶K（Cat K）抑制剂的合成和生物学特性。对12的药代动力学评估表明，该系列的某些成员可能是开发新型口服活性治疗剂以治疗骨质疏松症的合适人选。

  DOI：

  10.1016/j.bmcl.2006.05.061
• 作为产物：
  描述：

  3-(二甲氨基)吡咯烷 在 氨 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 16.0h， 生成 3-二甲基氨基吡咯烷e-1-硫代甲酰胺
  参考文献：
  名称：

  组织蛋白酶K的四环非肽联芳腈抑制剂的设计与合成。

  摘要：

  描述了一系列新型和有效的半胱氨酸蛋白酶组织蛋白酶K（Cat K）抑制剂的合成和生物学特性。对12的药代动力学评估表明，该系列的某些成员可能是开发新型口服活性治疗剂以治疗骨质疏松症的合适人选。

  DOI：

  10.1016/j.bmcl.2006.05.061

文献信息

• [EN] PYRIDAZINONE DERIVATIVES CYTOKINES INHIBITORS<br/>[FR] DÉRIVÉS DE LA PYRIDAZINONE INHIBITEURS DE CYTOKINES
  申请人：ASTELLAS PHARMA INC

  公开号：WO2006038734A1

  公开（公告）日：2006-04-13

  A pyridazinone derivative shown by the following formula (I): wherein; which is useful as a medicament for cytokines mediated diseases.

  以下是公式（I）所示的吡啶并嗪酮衍生物；其中；该衍生物在细胞因子介导的疾病的药物中有用。
• Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
  申请人：——

  公开号：US20030105071A1

  公开（公告）日：2003-06-05

  One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.

  本发明的一个方面涉及新颖的杂环化合物。本发明的第二个方面涉及将这些新颖的杂环化合物用作各种哺乳动物细胞受体的配体，包括G蛋白偶联受体。本发明的第三个方面涉及将这些新颖的杂环化合物用作哺乳动物多巴胺、肌肉或血清素受体或转运体的配体。本发明的另一个方面涉及将这些新颖的杂环化合物用作哺乳动物多巴胺、肌肉或血清素受体的配体。本发明的化合物还将用于治疗许多困扰哺乳动物的疾病、症状和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖、呕吐、精神病、镇痛、精神分裂症、帕金森病、不宁腿综合征、睡眠障碍、注意力缺陷多动障碍、肠易激综合征、早泄、月经痛综合征、尿失禁、炎症性疼痛、神经痛、Lesche-Nyhane病、威尔逊病、抽动症、精神障碍、中风、老年性痴呆、消化性溃疡、肺阻塞疾病和哮喘。
• Design and Synthesis of Tri-Ring P₃ Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K
  作者：James T. Palmer、Clifford Bryant、Dan-Xiong Wang、Dana E. Davis、Eduardo L. Setti、Robert M. Rydzewski、Shankar Venkatraman、Zong-Qiang Tian、Leland C. Burrill、Rohan V. Mendonca、Eric Springman、John McCarter、Tobee Chung、Harry Cheung、James W. Janc、Mary McGrath、John R. Somoza、Philip Enriquez、Z. Walter Yu、Robert M. Strickley、Liang Liu、Michael C. Venuti、M. David Percival、Jean-Pierre Falgueyret、Peppi Prasit、Renata Oballa、Denis Riendeau、Robert N. Young、Gregg Wesolowski、Sevgi B. Rodan、Colena Johnson、Donald B. Kimmel、Gideon Rodan

  DOI：10.1021/jm058198r

  日期：2005.12.1

  We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P-2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/ L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.
• US6699866B2
  申请人：——

  公开号：US6699866B2

  公开（公告）日：2004-03-02
• US7087623B2
  申请人：——

  公开号：US7087623B2

  公开（公告）日：2006-08-08